Baricitinib works better than methotrexate for severe alopecia areata.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
1 citations
,
March 2017 in “European Journal of Cancer Prevention”
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
46 citations
,
May 2021 in “Stem Cell Research & Therapy” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
December 2024 in “Jurnal Mandala Pharmacon Indonesia” Ramania leaf extract is non-toxic but can cause stomach ulcers at high doses.
1 citations
,
May 2022 in “International Journal of Pharmaceutical Sciences and Drug Research” Hibiscus syriacus L. flower extracts may help lower blood sugar and improve cholesterol in diabetes.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
1 citations
,
May 2025 in “Archives of Dermatological Research”
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Rosary Pea has medicinal benefits but requires careful handling due to its toxicity.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
13 citations
,
September 2011 in “International Urology and Nephrology” April 2026 in “Phytotherapy Research” Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
June 2024 in “The Journal of Dermatology” 10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
1 citations
,
October 2002 in “The Journal of Urology”
October 2008 in “Journal of Intellectual Property Law & Practice” The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.